Can hyperbaric oxygen be used as adjunctive heart failure therapy through the induction of endogenous heat shock proteins?

Advances in Therapy

Volumn 24, Issue 1, 2007, Pages 106-118

  Yogaratnam, Jeysen Zivan ^a   Laden, Gerard ^b   Guvendik, Levant ^a   Cowen, Mike ^a   Cale, Alex ^a   Griffin, Steve ^a  

^a CASTLE HILL HOSPITAL   (United Kingdom)

^b Classic Hospital   (United Kingdom)

Author keywords

Heart failure; Heat shock protein; Hyperbaric oxygen

Indexed keywords

ALTEPLASE; BRAIN NATRIURETIC PEPTIDE; CHAPERONE; DIURETIC AGENT; HEAT SHOCK PROTEIN 70; INOTROPIC AGENT; LEVOSIMENDAN; OXYGEN; STREPTOKINASE; TEZOSENTAN; VASODILATOR AGENT;

AGING; ARTICLE; BLOOD CLOT LYSIS; CORONARY ARTERY BLOOD FLOW; COST BENEFIT ANALYSIS; DISEASE COURSE; DRUG EFFECT; HEALTH CARE; HEART FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART STRESS; HEART VENTRICLE FUNCTION; HUMAN; HYPERBARIC OXYGEN; LIFE EXPECTANCY; MONOTHERAPY; MORBIDITY; PRODUCTIVITY; PROTEIN EXPRESSION; PROTEIN INDUCTION; REPERFUSION INJURY; RISK FACTOR;

ANIMALS; COMBINED MODALITY THERAPY; HEART FAILURE, CONGESTIVE; HEAT-SHOCK PROTEINS; HUMANS; HYPERBARIC OXYGENATION; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS;

EID: 34247891630     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849998     Document Type: Article

References (81)

1. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. Executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1995 guidelines for the evaluation and management of heart failure): developed in collaboration with the International Society for Heart and Lung Transplantation (endorsed by the Heart Failure Society of America). Circulation. 2001;104:2996-3007.
2. Aghababian RV. Acutely decompensated heart failure: opportunities to improve care and outcomes in the emergency department. Rev Cardiovasc Med. 2002;3(suppl 4):S3-S9.
3. Thorn T, Haase N, Rosamond W, et al. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006;113:e85-e151.
4. Graves EJ, Kozak LJ. National hospital discharge survey: annual summary, 1996. Vital Health Stal. 1999;13:i-iv,1-46.
5. Schocken DD, Arrieta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301-306.
6. Fonarow GC. The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(suppl 7):S21-S30.
7. Jong P, Vowinckel E, Liu PP, Gong Y, Tu JV. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population-based study. Arch Intern Med. 2002;162:1689-1694.
8. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 1993;88:107-115.
9. Berry C, Murdoch DR, McMurray JJ. Economics of chronic heart failure. Eur J Heart Fail. 2001;3:283-291.
10. Blackledge HM, Tomlinson J, Squire IB. Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12,220 index admissions in Leicestershire 1993-2001. Heart. 2003;89:615-620.
11. Wong PS, Davidsson GK, Timeyin J, et al. Heart failure in patients admitted to hospital: mortality is still high. Eur J Intern Med. 2002;13:304-310.
12. Khand AU, Gemmell I, Rankin AC, Cleland JG. Clinical events leading to the progression of heart failure: insights from a national database of hospital discharges. Eur Heart J. 2001;22:153-164.
13. Cowie MR, Wood DA, Coats AJ, et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 2000;83:505-510.
14. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovasc Pathol. 2005;14:170-175.
15. Mehra MR. Optimizing outcomes in the patient with acute decompensated heart failure. Am Heart J. 2006;151:571-579.
16. Yacoub MH, Zeitlin GL. Hyperbaric oxygen in the treatment of the postoperative low-cardiac-output syndrome. Lancet. 1965;191581-583.
17. Figueredo VM, Camacho SA. Basic mechanisms of myocardial dysfunction: cellular pathophysiology of heart failure. Curr Opin Cardiol. 1994;9:272-279.
18. Swynghedauw B. Biological adaptation of the myocardium to a permanent change in loading conditions. Basic Res Cardiol. 1992;87(suppl 2):1-10.
19. Skeletal muscle in heart failure. Lancet 1992;340:1383-1384.
20. Drexler H, Riede U, Munzel T, Konig H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation. 1992;85:1751-1759.
21. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A. Plasma norepinephrine, plasma renin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993;87(6 suppl):V140-V148.
22. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of congestive state in chronic obstructive pulmonary disease: studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation. 1992;86:12-21.
23. Packer M, Lee WH, Kessler PD, Gottlieb SS, Bernstein JL, Kukin ML. Role of neurohormonal mechanisms in determining survival in patients with severe chronic heart failure. Circulation. 1987;75:IV80-IV92.
24. Harris P. Role of arterial pressure in the oedema of heart disease. Lancet. 1988;1:1036-1038.
25. Delcayre C, Samuel JL, Marotte F, Best-Belpomme M, Mercadier JJ, Rappaport L. Synthesis of stress proteins in rat cardiac myocytes 2-4 days after imposition of hemodynamic overload. J Clin Invest. 1988;82:460-468.
26. Comini L, Gaia G, Curello S, et al. Right heart failure chronically stimulates heat shock protein 72 in heart and liver but not in other tissues. Cardiovasc Res. 1996;31:882-890.
27. Yellon DM, Latchman DS. Stress proteins and myocardial protection. J Mol Cell Cardiol. 1992;24:113-124.
28. Howard G, Geoghegan TE. Altered cardiac tissue gene expression during acute hypoxic exposure. Mol Cell Biochem. 1986;69:155-160.
29. Schlesinger MJ. Heat shock proteins: the search for functions. J Cell Biol. 1986;103:321-325.
30. Ang D, Liberek K, Skowyra D, Zylicz M, Georgopoulos C. Biological role and regulation of the universally conserved heat shock proteins. J Biol Chem. 1991;266:24233-24236.
31. Trost SU, Omens JH, Karlon WJ, et al. Protection against myocardial dysfunction after a brief ischemic period in transgenic mice expressing inducible heat shock protein 70. J Clin Invest. 1998;101:855-862.
32. Knowlton AA, Eberli FR, Brecher P, Romo GM, Owen A, Apstein CS. A single myocardial stretch or decreased systolic fiber shortening stimulates the expression of heat shock protein 70 in the isolated, erythrocyte-perfused rabbit heart. J Clin Invest. 1991;88:2018-2025.
33. Dybdahl B, Wahba A, Lien E, et al. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation. 2002;105:685-690.
34. Ferrari R, Bongrazio M, Cargnoni A, et al. Heat shock protein changes in hibernation: a similarity with heart failure? J Mol Cell Cardiol. 1996;28:2383-2395.
35. Lefer DJ, Granger DN. Oxidative stress and cardiac disease. Am J Med. 2000;109:315-323.
36. Santoro MG. Heat shock factors and the control of the stress response. Biochem Pharmacol. 2000;59:55-63.
37. Li Z, Menoret A, Srivastava P. Roles of heat-shock proteins in antigen presentation and cross-presentation. Curr Opin Immunol. 2002;14:45-51.
38. Feder ME, Hofmann GE. Heat-shock proteins, molecular chaperones, and the stress response: evolutionary and ecological physiology. Annu Rev Physiol. 1999;61:243-282.
39. Currie RW, Karmazyn M, Kloc M, Mailer K. Heat-shock response is associated with enhanced postischemic ventricular recovery. Circ Res. 1988;63:543-549.
40. Karmazyn M, Mailer K, Currie RW. Acquisition and decay of heat-shock-enhanced postischemic ventricular recovery. Am J Physiol. 1990;259:H424-H431.
41. Mocanu MM, Steare SE, Evans MC, Nugent JH, Yellon DM. Heat stress attenuates free radical release in the isolated perfused rat heart. Free Radic Biol Med. 1993;15:459-463.
42. Pockley AG. Heat shock proteins, inflammation, and cardiovascular disease. Circulation. 2002;105:1012-1017.
43. Malhotra V, Wong HR. Interactions between the heat shock response and the nuclear factor-kappaB signaling pathway. Crit Care Med. 2002;30(1 suppl):S89-S95.
44. Grunenfelder J, Zund G, Stucki V, et al. Heat shock protein upregulation lowers cytokine levels after ischemia and reperfusion. Eur Surg Res. 2001;33:383-387.
45. Frangogiannis NG, Youker KA, Rossen RD, et al. Cytokines and the microcirculation in ischemia and reperfusion. J Mol Cell Cardiol. 1998;30:2567-2576.
46. Balligand JL. Regulation of cardiac beta-adrenergic response by nitric oxide. Cardiovasc Res. 1999;43:607-620.
47. Paulus WJ, Frantz S, Kelly RA. Nitric oxide and cardiac contractility in human heart failure: time for reappraisal. Circulation. 2001;104:2260-2262.
48. Xie YW, Shen W, Zhao G, Xu X, Wolin MS, Hintze TH. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro: implications for the development of heart failure. Circ Res. 1996;79:381-387.
49. Paulus WJ, Vantrimpont PJ, Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans: assessment by bicoronary sodium nitroprusside infusion. Circulation. 1994;89:2070-2078.
50. Latchman DS. Heat shock proteins and cardiac protection. Cardiovasc Res. 2001;51:637-646.
51. Zingarelli B, Hake PW, Yang Z, O'Connor M, Denenberg A, Wong HR. Absence of inducible nitric oxide synthase modulates early reperfusion-induced NF-kappaB and AP-1 activation and enhances myocardial damage. FASEB J. 2002;16:327-342.
52. Al-Waili NS, Butler GJ, Beale J, et al. Hyperbaric oxygen in the treatment of patients with cerebral stroke, brain trauma, and neurologic disease. Adv Ther. 2005;22:659-678.
53. Imperatore F, Cuzzocrea S, Luongo C, et al. Hyperbaric oxygen therapy prevents vascular derangement during zymosan-induced multiple-organ-failure syndrome. Intensive Care Med. 2004;30:1175-1181.
54. Oter S, Edremitlioglu M, Korkmaz A, et al. Effects of hyperbaric oxygen treatment on liver functions, oxidative status and histology in septic rats. Intensive Care Med. 2005;31:1262-1268.
55. Cuzzocrea S, Imperatore F, Costantino G, et al. Role of hyperbaric oxygen exposure in reduction of lipid peroxidation and in multiple organ failure induced by zymosan administration in the rat. Shock. 2000;13:197-203.
56. Sterling DL, Thornton JD, Swafford A, et al. Hyperbaric oxygen limits infarct size in ischemic rabbit myocardium in vivo. Circulation. 1993;88:1931-1936.
57. Dekleva M, Neskovic A, Vlahovic A, Putnikovic B, Beleslin B, Ostojic M. Adjunctive effect of hyperbaric oxygen treatment after thrombolysis on left ventricular function in patients with acute myocardial infarction. Am Heart J. 2004;148:E14.
58. Vlahovic A, Neskovic AN, Dekleva M, et al. Hyperbaric oxygen treatment does not affect left ventricular chamber stiffness after myocardial infarction treated with thrombolysis. Am Heart J. 2004;148:e1.
59. Shandling AH, Ellestad MH, Hart GB, et al. Hyperbaric oxygen and thrombolysis in myocardial infarction: the "HOT MI" pilot study. Am Heart J. 1997;134:544-550.
60. Stavitsky Y, Shandling AH, Ellestad MH, et al. Hyperbaric oxygen and thrombolysis in myocardial infarction: the "HOT MI" randomized multicenter study. Cardiology. 1998;90:131-136.
61. Swift PC, Turner JH, Oxer HF, O'Shea JP, Lane GK, Woollard KV. Myocardial hibernation identified by hyperbaric oxygen treatment and echocardiography in postinfarction patients: comparison with exercise thallium scintigraphy. Am Heart J. 1992;124:1151-1158.
62. Thurston JG, Greenwood TW, Bending MR, Connor H, Curwen MP. A controlled investigation into the effects of hyperbaric oxygen on mortality following acute myocardial infarction. Q J Med. 1973;42:751-770.
63. Sharifi M, Fares W, Abdel-Karim I, Koch JM, Sopko J, Adler D. Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris. Am J Cardiol. 2004;93:1533-1535.
64. Kudchodkar BJ, Wilson J, Lacko A, Dory L. Hyperbaric oxygen reduces the progression and accelerates the regression of atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 2000;20:1637-1643.
65. Kjeldsen K, Astrup P, Wanstrup J. Reversal of rabbit atheromatosis by hyperoxia. J Atheroscler Res. 1969;10:173-178.
66. Vesselinovitch D, Wissler RW, Fisher-Dzoga K, Hughes R, Dubien L. Regression of atherosclerosis in rabbits. I. Treatment with low-fat diet, hyperoxia and hypolipidemic agents. Atherosclerosis. 1974;19:259-275.
67. Bennett M, Jepson N, Lehm J. Hyperbaric oxygen therapy for acute coronary syndrome. Cochrane Database Syst Rev. 2005;CD004818.
68. Lopez-Ongil S, Hernandez-Perera O, Navarro-Antolin J, et al. Role of reactive oxygen species in the signalling cascade of cyclosporine A-mediated up-regulation of eNOS in vascular endothelial cells. Br J Pharmacol. 1998;124:447-454.
69. Thorn SR, Fisher D, Zhang J, et al. Stimulation of perivascular nitric oxide synthesis by oxygen. Am J Physiol Heart Circ Physiol. 2003;284:H1230-H1239.
70. Buras JA, Stahl GL, Svoboda KK, Reenstra WR. Hyperbaric oxygen downregulates 1CAM-1 expression induced by hypoxia and hypoglycemia: the role of NOS. Am J Physiol Cell Physiol. 2000;278:C292-C302.
71. Cabigas BP, Su J, Hutchins W, et al. Hyperoxic and hyperbaric-induced cardioprotection: role of nitric oxide synthase 3. Cardiovasc Res. 2006;72:143-151.
72. Shyu WC, Lin SZ, Saeki K, et al. Hyperbaric oxygen enhances the expression of prion protein and heat shock protein 70 in a mouse neuroblastoma cell line. Cell Mol Neurobiol. 2004;24:257-268.
73. Thorn SR, Bhopale V, Fisher D, Manevich Y, Huang PL, Buerk DG. Stimulation of nitric oxide synthase in cerebral cortex due to elevated partial pressures of oxygen: an oxidative stress response. J Neurobiol. 2002;51:85-100.
74. Dennog C, Radermacher P, Barnett YA, Speit G. Antioxidant status in humans after exposure to hyperbaric oxygen. Mutat Res. 1999;428:83-89.
75. Wada K, Ito M, Miyazawa T, et al. Repeated hyperbaric oxygen induces ischemic tolerance in gerbil hippocampus. Brain Res. 1996;740:15-20.
76. Nylander G, Nordstrom H, Lewis D, Larsson J. Metabolic effects of hyperbaric oxygen in postischemic muscle. Plast Reconstr Surg. 1987;79:91-97.
77. Yamada T, Taguchi T, Hirata Y, Suita S, Yagi H. The protective effect of hyperbaric oxygenation on the small intestine in ischemia-reperfusion injury. J Pediatr Surg. 1995;30:786-790.
78. Chen MF, Chen HM, Ueng SW, Shyr MH. Hyperbaric oxygen pretreatment attenuates hepatic reperfusion injury. Liver. 1998;18:110-116.
79. Calvert JW, Yin W, Patel M, et al. Hyperbaric oxygenation prevented brain injury induced by hypoxia-ischemia in a neonatal rat model. Brain Res. 2002;951:1-8.
80. Benson RM, Minter LM, Osborne BA, Granowitz EV. Hyperbaric oxygen inhibits stimulus-induced proinflammatory cytokine synthesis by human blood-derived monocyte-macrophages. Clin Exp Immunol. 2003;134:57-62.
81. Weisz G, Lavy A, Adir Y, et al. Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by circulating monocytes during hyperbaric oxygen treatment in patients with perianal Crohn's disease. J Clin Immunol. 1997;17:154-159.